LA General) Internal Medicine

Topics

• Hepatitis B Virus Studies 137
• Sexual function and dysfunction studies 102
• Hepatitis C virus research 97
• Pancreatic and Hepatic Oncology Research 96
• Hepatocellular Carcinoma Treatment and Prognosis 80
• Menopause: Health Impacts and Treatments 77
• Venous Thromboembolism Diagnosis and Management 69
• HIV/AIDS Research and Interventions 62
• Cancer Immunotherapy and Biomarkers 61
• Liver Disease Diagnosis and Treatment 61
• Cardiac Imaging and Diagnostics 60
• Liver Disease and Transplantation 59

Most cited

1. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

   Lancet (London, England) · 2025 · 275 citations · Anthony El-Khoueiry

2. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

   The Lancet. Oncology · 2022 · 997 citations · Anthony El-Khoueiry

3. Ponsegromab for the Treatment of Cancer Cachexia.

   The New England journal of medicine · 2024 · 260 citations · Andrew Hendifar

4. Emotion regulation in substance use disorders: a systematic review and meta-analysis.

   Addiction (Abingdon, England) · 2023 · 198 citations · Jordan Stellern

5. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

   The Lancet. Oncology · 2021 · 510 citations · Andrew Hendifar

6. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · 270 citations ·